Building a Tardive Dyskinesia Center of Excellence: A Multidisciplinary Model

figure img { width:100% !important; } figcaption { padding: 5px; background: transparent; word-wrap: normal; text-align: center; font-size:10px; line-height: 12px; }Credit: @McMahon Group.By Gina ShawFive years ago, clinicians treating tardive dyskinesia (TD) had little to offer beyond dose adjustments and monitoring. Today, vesicular monoamine transporter 2 (VMAT2) inhibitors have changed the therapeutic landscape. But according to Swati Pradeep, DO, an assistant professor of neurology at McGov